#151571

Anti-BRCA2 [MTA42]

Cat. #151571

Anti-BRCA2 [MTA42]

Cat. #: 151571

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: BRCA2

Class: Polyclonal

Application: ChIP ; IP ; WB

Reactivity: Human ; Mouse

Host: Rabbit

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Madalena Tarsounas

Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-BRCA2 [MTA42]
  • Alternate name: BRCA 2, BRCA1/BRCA2 containing complex subunit 2, Brca2, BRCA2_HUMAN, BRCC 2, BRCC2, Breast and ovarian cancer susceptibility gene early onset, Breast cancer 2 early onset, Breast Cancer 2 tumor suppressor, Breast cancer susceptibility protein BRCA2, Breast cancer type 2 susceptibility protein, BROVCA2, FACD, FAD 1, FAD, FAD1, FANCB, FANCD 1
  • Clone: MTA42
  • Tool sub type: Primary antibody
  • Class: Polyclonal
  • Conjugation: Unconjugated
  • Molecular weight: 370 kDa
  • Reactivity: Human ; Mouse
  • Host: Rabbit
  • Application: ChIP ; IP ; WB
  • Description: Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer.
  • Immunogen: Human BRCA2 sequence
  • Recommended controls: HeLa and U2OS human cells

Target Details

  • Target: BRCA2
  • Molecular weight: 370 kDa
  • Tissue cell line specificity: HeLa and U2OS human cells
  • Target background: Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer.

Applications

  • Application: ChIP ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1.47 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS, 0.1% NaN3
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Zhang et al. 2012. Clin Cancer Res. 18(21):5961-71. PMID: 22977194.
  • FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
  • Badie et al. 2010. Nat Struct Mol Biol. 17(12):1461-9. PMID: 21076401.
  • BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.